FDA inspection
Pfizer Inc.: FDA inspection ending Apr 18, 2006
FDA inspection 422082 · Voluntary Action Indicated (VAI) · New York, NY
Key facts
| Inspection ID | 422082 |
|---|---|
| Firm | Pfizer Inc. |
| FEI number | 2416101 |
| Address | 235 East 42nd Street |
| City | New York |
| State | NY |
| ZIP | 10017-5703 |
| Fiscal year | 2006 |
| Inspection end date | Apr 18, 2006 |
| Classification | Voluntary Action Indicated (VAI) |
| Project area | Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Post Mrkt Surv & Epid: Human Drugs|Unapproved and Misbranded Drugs|Post Mrkt Surv & Epid: Human Drugs|Unapproved and Misbranded Drugs|Post Mrkt Surv & Epid: Human Drugs|Unapproved and Misbranded Drugs|Post Mrkt Surv & Epid: Human Drugs|Unapproved and Misbranded Drugs|Post Mrkt Surv & Epid: Human Drugs|Unapproved and Misbranded Drugs|Post Mrkt Surv & Epid: Human Drugs|Unapproved and Misbranded Drugs|Post Mrkt Surv & Epid: Human Drugs|Unapproved and Misbranded Drugs|Post Mrkt Surv & Epid: Human Drugs|Unapproved and Misbranded Drugs|Post Mrkt Surv & Epid: Human Drugs|Unapproved and Misbranded Drugs|Post Mrkt Surv & Epid: Human Drugs|Unapproved and Misbranded Drugs|Post Mrkt Surv & Epid: Human Drugs|Unapproved and Misbranded Drugs|Post Mrkt Surv & Epid: Human Drugs|Unapproved and Misbranded Drugs|Post Mrkt Surv & Epid: Human Drugs|Unapproved and Misbranded Drugs|Post Mrkt Surv & Epid: Human Drugs|Unapproved and Misbranded Drugs|Post Mrkt Surv & Epid: Human Drugs|Unapproved and Misbranded Drugs|Post Mrkt Surv & Epid: Human Drugs|Unapproved and Misbranded Drugs|Post Mrkt Surv & Epid: Human Drugs|Unapproved and Misbranded Drugs|Post Mrkt Surv & Epid: Human Drugs|Unapproved and Misbranded Drugs|Post Mrkt Surv & Epid: Human Drugs|Unapproved and Misbranded Drugs|Post Mrkt Surv & Epid: Human Drugs|Unapproved and Misbranded Drugs|Post Mrkt Surv & Epid: Human Drugs|Unapproved and Misbranded Drugs|Post Mrkt Surv & Epid: Human Drugs|Unapproved and Misbranded Drugs|Post Mrkt Surv & Epid: Human Drugs|Unapproved and Misbranded Drugs|Post Mrkt Surv & Epid: Human Drugs|Unapproved and Misbranded Drugs|Post Mrkt Surv & Epid: Human Drugs|Unapproved and Misbranded Drugs|Post Mrkt Surv & Epid: Human Drugs|Unapproved and Misbranded Drugs|Post Mrkt Surv & Epid: Human Drugs|Unapproved and Misbranded Drugs|Post Mrkt Surv & Epid: Human Drugs|Unapproved and Misbranded Drugs|Post Mrkt Surv & Epid: Human Drugs|Unapproved and Misbranded Drugs|Post Mrkt Surv & Epid: Human Drugs|Unapproved and Misbranded Drugs|Post Mrkt Surv & Epid: Human Drugs|Unapproved and Misbranded Drugs|Post Mrkt Surv & Epid: Human Drugs|Unapproved and Misbranded Drugs|Post Mrkt Surv & Epid: Human Drugs|Unapproved and Misbranded Drugs|Post Mrkt Surv & Epid: Human Drugs|Unapproved and Misbranded Drugs|Post Mrkt Surv & Epid: Human Drugs|Unapproved and Misbranded Drugs|Post Mrkt Surv & Epid: Human Drugs|Unapproved and Misbranded Drugs|Post Mrkt Surv & Epid: Human Drugs|Unapproved and Misbranded Drugs|Post Mrkt Surv & Epid: Human Drugs|Unapproved and Misbranded Drugs|Post Mrkt Surv & Epid: Human Drugs|Unapproved and Misbranded Drugs|Post Mrkt Surv & Epid: Human Drugs|Unapproved and Misbranded Drugs|Post Mrkt Surv & Epid: Human Drugs|Unapproved and Misbranded Drugs|Post Mrkt Surv & Epid: Human Drugs|Unapproved and Misbranded Drugs|Post Mrkt Surv & Epid: Human Drugs|Unapproved and Misbranded Drugs|Post Mrkt Surv & Epid: Human Drugs|Unapproved and Misbranded Drugs|Post Mrkt Surv & Epid: Human Drugs|Unapproved and Misbranded Drugs|Post Mrkt Surv & Epid: Human Drugs|Unapproved and Misbranded Drugs|Post Mrkt Surv & Epid: Human Drugs|Unapproved and Misbranded Drugs|Post Mrkt Surv & Epid: Human Drugs|Unapproved and Misbranded Drugs|Post Mrkt Surv & Epid: Human Drugs|Unapproved and Misbranded Drugs|Post Mrkt Surv & Epid: Human Drugs|Unapproved and Misbranded Drugs|Post Mrkt Surv & Epid: Human Drugs|Unapproved and Misbranded Drugs|Post Mrkt Surv & Epid: Human Drugs|Unapproved and Misbranded Drugs|Post Mrkt Surv & Epid: Human Drugs|Unapproved and Misbranded Drugs|Post Mrkt Surv & Epid: Human Drugs|Unapproved and Misbranded Drugs|Post Mrkt Surv & Epid: Human Drugs|Unapproved and Misbranded Drugs|Post Mrkt Surv & Epid: Human Drugs|Unapproved and Misbranded Drugs|Post Mrkt Surv & Epid: Human Drugs|Unapproved and Misbranded Drugs|Post Mrkt Surv & Epid: Human Drugs|Unapproved and Misbranded Drugs|Post Mrkt Surv & Epid: Human Drugs|Unapproved and Misbranded Drugs|Post Mrkt Surv & Epid: Human Drugs|Unapproved and Misbranded Drugs|Post Mrkt Surv & Epid: Human Drugs|Unapproved and Misbranded Drugs|Post Mrkt Surv & Epid: Human Drugs|Unapproved and Misbranded Drugs|Post Mrkt Surv & Epid: Human Drugs|Unapproved and Misbranded Drugs|Post Mrkt Surv & Epid: Human Drugs|Unapproved and Misbranded Drugs|Post Mrkt Surv & Epid: Human Drugs|Unapproved and Misbranded Drugs|Post Mrkt Surv & Epid: Human Drugs|Unapproved and Misbranded Drugs|Post Mrkt Surv & Epid: Human Drugs|Unapproved and Misbranded Drugs|Post Mrkt Surv & Epid: Human Drugs|Unapproved and Misbranded Drugs|Post Mrkt Surv & Epid: Human Drugs|Unapproved and Misbranded Drugs|Post Mrkt Surv & Epid: Human Drugs|Unapproved and Misbranded Drugs|Post Mrkt Surv & Epid: Human Drugs|Unapproved and Misbranded Drugs |
| Product type | Drugs |
At a glance
- 1–9 Citations
- 1–9 Posted citations
- No Warning letter followed
- Yes Form FDA 483 issued
- Yes Establishment inspection report (EIR) exists
- 10–99 Inspections at this FEI
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About FDA inspections
FDA inspections are classified as No Action Indicated (NAI), Voluntary Action Indicated (VAI) or Official Action Indicated (OAI). Inspections of individual clinical investigators are not published here.
Source: U.S. Food and Drug Administration (FDA), inspection classification data